Scarica l'app Stockscreener
16.66
0.36%
-0.06
Dopo l'orario di chiusura:
16.90
0.24
+1.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
(DNLI) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
First Week of June 2026 Options Trading For Denali Therapeutics (DNLI) - Nasdaq
Full technical analysis of Denali Therapeutics Inc. stockEarnings Beat & Weekly High Conviction Trade Ideas - newser.com
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034 - GlobeNewswire Inc.
Is Denali Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com
Is Denali Therapeutics Inc. stock a top momentum playMarket Volume Report & Smart Money Movement Alerts - newser.com
Denali Therapeutics stock faces FDA delay as H.C. Wainwright maintains Buy rating - Investing.com India
Will Denali Therapeutics Inc. stock rally after Fed decisionsTrade Analysis Report & Risk Managed Trade Strategies - newser.com
Denali Therapeutics Inc. (4DN.F) stock price, news, quote and history - Yahoo
Denali Therapeutics: PDUFA Countdown For Tividenofusp Marks A Defining Moment (NASDAQ:DNLI) - Seeking Alpha
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate - Benzinga
Stifel reiterates Buy rating on Denali Therapeutics stock amid FDA review delay - Investing.com UK
[8-K] – Denali Therapeutics Inc. (DNLI) (CIK 0001714899) | DNLI SEC FilingForm 8-K - Stock Titan
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Yahoo Finance
Denali Therapeutics Inc Announces FDA Review Extension for Tividenofusp Alfa - TradingView
[8-K] Denali Therapeutics Inc. Reports Material Event | DNLI SEC FilingForm 8-K - Stock Titan
Is Denali Therapeutics Inc a good long term investmentBullish Engulfing Patterns & Low Cost Stock Picks - earlytimes.in
Denali Therapeutics gets FDA review extension for tividenofusp alfa - Seeking Alpha
Denali Therapeutics announces FDA review extension of BLA for Tividenofusp alfa - MarketScreener
Denali Therapeutics Announces FDA Review Extension Of BLA For Tividenofusp Alfa - TradingView
Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment - Quiver Quantitative
FDA extends review of Denali’s Hunter syndrome treatment - Investing.com
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) - Stock Titan
Published on: 2025-10-13 08:56:53 - earlytimes.in
Tangible book value per share of Denali Therapeutics Inc. – SWB:4DN - TradingView
Denali Therapeutics Inc.Common Stock (Nasdaq:DNLI) Detailed Stock Data - FinancialContent
Denali Therapeutics Inc (4DN.BE) Stock Price, News, Quote & History - Yahoo
Denali Therapeutics Inc (4DN.BE) stock price, news, quote and history - Yahoo
Understanding Denali Therapeutics Inc.’s price movementMarket Risk Analysis & Low Volatility Stock Suggestions - newser.com
How to forecast Denali Therapeutics Inc. trends using time seriesWeekly Trend Summary & Advanced Swing Trade Entry Alerts - newser.com
Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Tick level data insight on Denali Therapeutics Inc. volatilityTrend Reversal & Reliable Volume Spike Alerts - newser.com
Forecasting Denali Therapeutics Inc. price range with options data2025 Year in Review & Fast Entry High Yield Stock Tips - newser.com
What institutional flow reveals about Denali Therapeutics Inc.Quarterly Growth Report & Verified Swing Trading Watchlist - newser.com
Will Denali Therapeutics Inc. bounce back from current supportWeekly Trade Review & High Conviction Buy Zone Alerts - newser.com
Denali Therapeutics' (DNLI) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Denali Therapeutics Inc. (DNLI) Stock Analysis: A Biotech Pioneer with Over 107% Upside Potential - DirectorsTalk Interviews
What the Next Quarters Forecast Means for Beacon Trusteeship Limited InvestorsQuarterly Earnings Review & Free Tools to Find Winning Stocks - earlytimes.in
Denali Therapeutics Inc 4DN Stock Analysis and ForecastSector Performance Review & Get Free Expert Trading Recommendations - earlytimes.in
How to monitor Denali Therapeutics Inc. with trend dashboardsJuly 2025 Opening Moves & Consistent Profit Trade Alerts - newser.com
Regression analysis insights on Denali Therapeutics Inc. performanceBull Run & Consistent Return Strategy Ideas - newser.com
Should you hold or exit Denali Therapeutics Inc. nowJuly 2025 Institutional & Verified Swing Trading Watchlist - newser.com
Visual analytics tools that track Denali Therapeutics Inc. performanceTake Profit & Weekly Breakout Stock Alerts - newser.com
Deutsche Bank sets $31 target for Denali Therapeutics stock - MSN
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
Why Denali Therapeutics Inc. stock attracts global investorsPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - newser.com
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):